Impact of Intrapartum Oral Azithromycin on the Acquired Macrolide Resistome of Infants' Nasopharynx: A Randomized Controlled Trial.
Bojang, A
; Baines, SL; Camara, B; Guerillot, R; Donovan, L; Marqués, RS; Secka, O; D'Alessandro, U; Bottomley, C; Howden, BP; +1 more...Roca, A and
(2020)
Impact of Intrapartum Oral Azithromycin on the Acquired Macrolide Resistome of Infants' Nasopharynx: A Randomized Controlled Trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 71 (12).
pp. 3222-3225.
ISSN 1058-4838
DOI: 10.1093/cid/ciaa609
; Baines, SL; Camara, B; Guerillot, R; Donovan, L; Marqués, RS; Secka, O; D'Alessandro, U; Bottomley, C; Howden, BP; +1 more...Roca, A and
(2020)
Impact of Intrapartum Oral Azithromycin on the Acquired Macrolide Resistome of Infants' Nasopharynx: A Randomized Controlled Trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 71 (12).
pp. 3222-3225.
ISSN 1058-4838
DOI: 10.1093/cid/ciaa609
UNLABELLED: In a post hoc analysis of samples from an intrapartum azithromycin randomized clinical trial, we found that children whose mothers had been treated with the drug had higher prevalence of macrolide-resistance genes msr(A) and ermC at 28 days but not at 12 months. The 2 genes were positively associated in the nasopharynx. CLINICAL TRIALS REGISTRATION: NCT1800942.
-
picture_as_pdf - Impact of Intrapartum Oral Azithromycin on the Acquired Macrolide Resistome of Infants Nasopharynx A Randomized Controlled T.pdf
-
subject - Published Version
-
- Available under Creative Commons: Attribution 3.0
Downloads